Thursday, May 23, 2019
engineered enzymes for better healthcare


Glucose-6P Dehydrogenase Deficiency (G6PD) is caused by a deficiency in the enzyme glucose-6P dehydrogenase needed to protect the organism and especially red blood cells against oxidative stresses. G6PD is included in newborn screening programmes in some countries, particularly in Asia and the Mediterranean, where it is the most common enzymopathy. The average incidence of G6PD in the world is approximately 1 in every 20,000 newborns, but newborn screening programmes in the Philippines and in Taiwan have reported much higher incidence figures of 1 in every 65. Untreated G6PD results in haemolytic anaemia, neonatal jaundice and neurological damage. Early detection and avoidance of certain medication, food containing fava beans, etc. can minimise most of the major complications connected with G6PD deficiency.

Product Info


amino acid disorders productEnzyme Deficiency Disorders

GAL      Galactosaemia

G6PD    Glucose-6P Dehydrogenase Deficiency

BIO       Biotinidase Deficiency


Language Selection


Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…


Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…


UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…